Vertex Pharmaceuticals (VRTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$546.12-2.12%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Vertex grows revenue about 8% yearly, driven by cystic fibrosis drugs. It launched JOURNAVX with $29 million revenue in Q1 2026. The company plans $13 billion revenue in 2026. Vertex expands into rare diseases with a $10 billion acquisition.
Growth could slow if new drug launches fail or approvals stall. Competition may reduce Vertex's market share. The $10 billion deal might not add expected revenue.
The stock trades about 35% above our fair value near $387. Analysts expect 11% revenue growth, slightly above our 10.4% implied growth.
Breaks if: YoY revenue growth falls below 6% next year
Breaks if: JOURNAVX revenue falls below $20 million next year
Acquisition fails to add meaningful revenue or delays occur
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a stable management team. The current thesis state is intact, supported by strong recent financial performance and ongoing product expansion.
The market appears to assume a high level of execution quality, reflected in an elevated valuation compared to peers. However, the expectations gap suggests that some of this premium may not be justified given recent execution challenges in the industry.
Management is likely to continue delivering strong growth in key areas, particularly cystic fibrosis and acute pain products. However, there is a moderate risk of missing expectations, especially as industry peers have faced challenges recently.
The long-term thesis hinges on maintaining guidance and avoiding credibility issues, as well as the overall health of the healthcare sector. Key forward scenarios include the performance of sector bellwethers and potential economic shifts affecting demand.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Vertex's latest earnings beat supports a stronger outlook. The company raised its 2026 revenue guidance, which reinforces growth expectations. A competitor's drug failed in trials, reducing competitive pressure in cystic fibrosis. This strengthens Vertex's market position for the foreseeable future.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: total revenue falls below $12.5 billion in FY26
In the next 1 to 3 years, Vertex Pharmaceuticals is positioned to capitalize on its growth initiatives, but it must navigate sector dynamics and execution risks. Not investment advice.